Corcept Therapeutics (CORT) Tops Q4 EPS by 4c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $111.62 -1.05%
Revenue Growth %: +54.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +54.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of ($0.02), $0.04 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $9.01 million versus the consensus estimate of $9.1 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy
- Dell’s earning report was bullish for Intel CPU demand, analyst says
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
